CASE REPORT

Recurrent autoimmune hypophysitis treated with rituximab: a case report

Maria Kruse, Thomas Bastholm Olesen, Ljubo Markovic, Dorte Glintborg and Marianne Skovsager Andersen

Abstract

Background: Autoimmune hypophysitis is a rare condition that often results in enlargement of the pituitary gland and hypopituitarism due to inflammatory infiltration. Management of autoimmune hypophysitis can include long-term hormonal replacement and close control of the inflammatory pituitary mass. Mass-related symptoms in patients with autoimmune hypophysitis are treated with anti-inflammatory therapy, surgery, and/or radiotherapy.

Case presentation: We present a 25-year-old White man with visual field defects of the right eye, headache, and weight loss. Magnetic resonance imaging showed a sellar mass, and the patient underwent transcranial surgery. Histopathology revealed autoimmune hypophysitis with predominantly CD20 positive B-cell infiltration. Progression of visual field defects necessitated postoperatively anti-inflammatory treatment with prednisolone. Azathioprine was initiated under gradual tapering of prednisolone with stable conditions at first, but relapse followed after dose reduction. Therefore, rituximab treatment was initiated, which resulted in regression of the pituitary mass. Rituximab treatment was discontinued after 25 months. The patient has continuously been in remission for 4 years after rituximab treatment was stopped.

Conclusion: This case illustrates that rituximab might be an effective alternative treatment in B-cell predominant autoimmune hypophysitis.

Keywords: Autoimmune hypophysitis, Lymphocytic hypophysitis, Primary hypophysitis, CD20+ B-cells, Immunotherapy, Monoclonal antibody, Rituximab

Background

Hypophysitis is a rare condition characterized by inflammatory infiltration of the pituitary gland. Hypophysitis can be divided into two main categories: primary hypophysitis (autoimmune, granulomatous, xanthomatous, immunoglobulin G4 (IgG4)-related, or necrotizing inflammation) and secondary hypophysitis. Primary hypophysitis has an incidence of ~1 in 9 million per year [1]. The most common form of primary hypophysitis is autoimmune hypophysitis (AH). AH has a strong female preponderance with the majority of cases identified during late pregnancy or postpartum. AH is confirmed histologically and immunohistochemically by lymphocytic infiltration (mostly T and B lymphocytes), plasma cells, histiocytes, and fibrosis [2, 3]. Secondary causes of hypophysitis include infectious and systemic diseases (such as systemic lupus erythematosus), sellar/parasellar lesions, and drug-therapy-induced hypophysitis [3–6].

Pituitary inflammation in hypophysitis usually results in enlargement of the pituitary gland with sellar compression and compression of the surrounding neurological structures including the optic chiasm. Therefore, patients often present with headache with or without nausea and visual disturbances [3]. The infiltrative inflammation of the pituitary gland can affect different parts of
the pituitary gland, resulting in a broad symptomatology including anterior pituitary hormone deficiencies, hyperprolactinemia, and diabetes insipidus. AH is considered to have a predilection to adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), gonadotropin hormone, and growth hormone deficiencies. ACTH and TSH deficiencies are very frequent in the early stages of AH unlike pituitary adenomas, which results in increased risk of life-threatening adrenal insufficiency [4, 7].

Typically, in primary hypophysitis, magnetic resonance imaging (MRI) of the sella region shows an enlarged symmetric homogeneous pituitary gland, a thickened but not deviated stalk, and an intact sellar floor [7]. MRI findings cannot distinguish hypophysitis from the more common differential diagnoses of pituitary mass, that is, pituitary adenomas, germinomas, Langerhans cell histiocytosis, and metastases. Approximately 40% of cases of primary hypophysitis are misdiagnosed preoperatively [8]. Histopathology is the gold standard for diagnosing hypophysitis. However, biopsy of a pituitary mass is rarely performed due to the risks of the procedure [3, 9]. Unlike other autoimmune endocrine diseases, measurement of anti-pituitary antibodies is not suitable for diagnosing AH [4, 7, 8, 10–12]. Thus, a presumptive diagnosis of hypophysitis is often due to a combination of clinical findings, radiology, and biochemical results [3, 4, 6].

Treatment of AH consists of managing pituitary enlargement and substituting acute and persistent pituitary hormone deficiencies. Reduction of the pituitary enlargement is required in some cases where mass effects are present. In asymptomatic cases, conservative treatment with close follow-up is an alternative. Pituitary enlargement can be reduced by anti-inflammatory therapy, surgery, stereotactic radiotherapy, or a combination of these types of intervention. High-dose glucocorticoids are the basis of anti-inflammatory therapy. Steroid-sparing agents such as azathioprine (an anti-metabolic agent with immunosuppressive activity) are considered in the case of relapse with mass-related symptoms or increased mass size on MRI, need of long-term anti-inflammatory treatment, or intolerable adverse effects to glucocorticoids. Rituximab, a monoclonal antibody that selectively induces apoptosis in B-lymphocytes, is approved for various immune-mediated disorders and has been used to manage recurrent AH in a few previous cases [3, 9–11, 13–15].

Case presentation
A previously healthy 25-year-old White man presented with a 1-year history of blurred vision in the right eye, headache, and weight loss of about 30 kg. On physical examination, he had a body mass index of 28 kg/m² and visual field defects in the right eye. Initial MRI showed a lightly spotted heterogeneous 19 × 16 × 19 mm tumor located suprasellarly, close to the pituitary gland with no ingrowth or association with the pituitary gland (Fig. 1A). Endocrine evaluation revealed secondary hypogonadism with low follicle-stimulating hormone, luteinizing hormone, and testosterone but intact thyrotroph and lactotroph axes. An ACTH test was performed with a subnormal cortisol response (30-minute cortisol 248 nmol/L, reference >420 nmol/L) and low plasma ACTH concentration, indicating secondary adrenal insufficiency, and the patient started treatment with hydrocortisone. The somatotroph axis was not evaluated. Visual field measured by perimetry revealed visual field defects in the right eye.

The tumor was initially diagnosed based on MRI as a craniopharyngioma for which reason the patient was referred to craniotomy as standard treatment. At surgery, the tumor appeared gray and reddish, and was capsulated and fragile with easy bleeding, unlike craniopharyngiomas with sharp, irregular borders, which have a tendency to adhere to vital neurovascular structures and often consist of cystic and/or solid parts [16]. The pituitary tumor was partially resected, and a small amount of capsule remnant underneath the optic chiasm could not be surgically removed. Perioperative frozen section histological examination described the tumor as a possible malignant lymphoma due to lymphocytic infiltration.

The patient was transferred to the Department of Endocrinology at Odense University Hospital for further diagnostic workup and management of pituitary hormone deficiencies. Postoperatively, the patient was still affected by headache and visual deficits on ophthalmologic assessment. MRI showed regression of the pituitary mass (9 × 6 × 8 mm), but remnant pituitary tissue was located just below the optic chiasm (Fig. 1B). Pituitary hormone insufficiency of all anterior axes and diabetes insipidus was diagnosed, and treatment with hydrocortisone, levothyroxine, testosterone, growth hormone, and desmopressin was implemented.

Endocrine evaluation did not support a hormone-producing adenoma. Sellar lymphoma is a very rare disease often related to immunodeficiency, for example HIV-related, or seen in immunocompetent patients who are over 60 years old [17]. Metastasis was not suspected; the patient did not suffer from cancer in another location. Workup for infectious and rheumatologic etiologies was not indicative of secondary hypophysitis, nor was drug-related infiltration of the pituitary gland a possible differential diagnosis. Final histological diagnosis showed lymphoid reaction with predominant CD20 positive B-cell infiltration and no sign of significant IgG4
involvement. The patient was diagnosed with autoimmune hypophysitis.

Ten months postoperatively, the patient reported impaired vision. MRI showed that the remnant tissue lifted and exerted pressure at the optic chiasm. Perimetry confirmed progression of visual field defects in the right eye and now involvement of the left eye. Because of progression of visual field defects, treatment with glucocorticoid pulse therapy was initiated: methylprednisolone 500 mg infusion for 3 days, followed by reduced prednisolone doses, that is, 37.5 mg per day. Follow-up MRI after 1 month of glucocorticoid treatment (11 months postoperatively) demonstrated significant reduction of the pituitary mass and decreased pressure at the optic chiasm. Perimetry was unchanged. Treatment with prednisolone continued for 3 months.

The patient had intolerable adverse effects to glucocorticoid treatment with excessive weight gain of about 50 kg and cushingoid features. The need for long-term treatment led to initiation of steroid-sparing treatment with 150 mg azathioprine per day under gradual tapering of prednisolone (13 months postoperatively). Visual field defects improved, and repeated MRI showed additional regression of the remnant pituitary mass. Perimetry revealed stable conditions. Due to stable condition over 26.5 months, treatment with azathioprine was reduced. Control MRI after one and a half month showed recurrence with increasing mass in sella turcica causing mass effect on the optic chiasm. Treatment was resumed: azathioprine 100 mg per day in combination with prednisolone 37.5 mg per day.

Despite additional 11 months treatment with azathioprine and prednisolone treatment (52 months postoperatively), control MRI showed further progression with increasing pituitary mass size ($11 \times 6 \times 7$ mm) reaching the optic chiasm (Fig. 1C). Treatment with rituximab was initiated: 1000 mg infusions 14 days apart, repeated every 12 months. This resulted in almost complete regression of pituitary mass ($3 \times 2 \times 7$ mm) evaluated by MRI (Fig. 1D). Rituximab treatment was discontinued after 25 months (77 months postoperatively) because of stable disease. To date, the patient has been followed up for ten and a half years postoperatively. According to control MRI 4 years after end of treatment with rituximab, he is in sustained remission with unchanged pituitary mass size and no affection of the optic chiasm.

**Discussions and conclusion**

AH progresses through initial stages of inflammation, lymphocyte infiltration, edema, and enlargement to fibrosis and subsequent atrophy [11]. Treatment with glucocorticoid pulse therapy has shown good response. In this case, the initial response to glucocorticoid
| Refs.          | Case characteristics                                      | Treatment                                      | Histology                                                                 | Outcome                                                                 |
|---------------|-----------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Xu et al. [14] | 54-year-old female with uveitis, scleritis, and diabetes insipidus | Infliximab and rituximab                      | CD20-positive B lymphocytes as the dominant cell type                      | Remission (follow-up 18 months)                                          |
| Schreckinger et al. [13] | 41-year-old female with visual loss in the left eye and sellar mass | Relapse at high-dose methylprednisolone. Changed to rituximab | CD20-positive B lymphocytes as the dominant cell type | Stable clinical and radiological improvement                              |
| De Bellis et al. [20] | 36-year-old male with primary immune thrombocytopenia (ITP) and hypogonadotropic hypogonadism | Rituximab                                      | Clinical diagnosis of autoimmune hypophysitis                              | Complete remission of ITP and autoimmune hypophysitis                    |
| Lecube et al. [19] | 53-year-old male with frontal headache, diplopia, and diabetes insipidus | Relapse at prednisolone. Changed to azathioprine | Mixed B and T lymphocytes                                                  | Complete resolution                                                       |
| Curto et al. [22] | 38-year-old male with diplopia, blurred vision, and headache | Relapse at high-dose methylprednisolone. Changed to azathioprine | Typical features of autoimmune hypophysitis                                | Decrease in pituitary mass                                               |
| Lu et al. [23] | 22-year-old female with headache, diplopia, left eye ptosis, and lactation | Relapse after transsphenoidal surgery. High-dose methylprednisolone and azathioprine | Lymphocytic, histiocytic, and neutrophil infiltration consistent with AH | Uneventful pregnancy and delivery                                        |
| Wang et al. [24] | 70-year-old female with diabetes insipidus and adenopituitary function deficiency | Relapse after glucocorticoid treatment High-dose methylprednisolone and azathioprine | Clinical diagnosis of autoimmune hypothalamitis No histopathology          | Long-term remission                                                     |
| Yang et al. [25] | 1) 22-year-old female with headache and diplopia 2) 70-year-old female with diabetes insipidus and dry mouth 3) 32-year-old female with diabetes insipidus, menstrual disorder, headache, and dizziness | Recurrence after surgery and prednisolone respectively. Changed to high-dose methylprednisolone followed by prednisolone and azathioprine for all cases | Lymphocytic infiltration in pituitary tissue in case 1 No other histopathology | Complete resolution on MRI with endocrine recovery in case 1 and 3 and permanent hypopituitarism in case 2 |
| Katsivali et al. [26] | 48-year-old female with headache, muscle weakness, and occlusion of both internal carotid arteries | Relapse when prednisolone tapering Due to adverse effects, treatment was changed to azathioprine | Clinically suspected AH No histopathology | Complete resolution and restored pituitary function                       |
| Curto et al. [27] | 38-year-old male with diplopia, ophthalmoplegia, and headache | Initial response on high-dose methylprednisolone. Changed to azathioprine | Lymphocytes with CD20-positive B cells and CD3-positive T cells            | No response to treatment                                                  |
treatment was good; however, the patient had intolerable adverse effects that led to change in treatment. Gutenberg et al. showed reduction in pituitary size in 75% of patients with AH during pre- or postsurgical glucocorticoid treatment [18]. However, relapse of AH is common and treatment with glucocorticoids, especially long-term treatment, is associated with a high risk of side effects (weight gain, psychiatric symptoms, edema, avascular bone necrosis, and diabetes mellitus). Honegger et al. showed a recurrence rate at 38% and found a high rate of significant adverse effects under glucocorticoid pulse therapy (63% of involved patients) [15].

If steroid treatment is discontinued either due to mass-related symptoms or due to intolerable adverse effects, other immunosuppressive therapy is considered. In this case, azathioprine was initiated under gradual tapering of prednisolone with stable conditions at first, but relapse followed after dose reduction. Azathioprine has been the most commonly used immunosuppressive agent; however, immunosuppressive or biological treatment directed at the predominant cell type involved may increase treatment efficacy [13, 14, 19]. The infiltration of the pituitary gland in AH is typically a mixture of T and B cells, often with one cell type being more predominant than the other. Most lympholytic drugs primarily target T cells, such as azathioprine, whereas rituximab specifically binds to the CD20 antigen on B lymphocytes, inducing apoptosis [13, 14]. Additionally, rituximab may reduce the antigen presentation, leading to T-cell inactivation [20, 21]. The potential effect of histologically guided treatment of AH is illustrated in a case reported by Xu et al. [14] The patient was initially treated with prednisolone and methotrexate without effect and afterwards treated with infliximab (a monoclonal antibody that antagonizes tumor necrosis factor alpha). Due to recurrence of pituitary enlargement, a transsphenoidal biopsy was performed, showing CD20 positive B lymphocytes as the dominant cell type. Subsequently, treatment with rituximab resulted in long-term remission [14].

Steroid-sparing treatment seems promising as a useful addition to glucocorticoids. There is no indication for rituximab in AH yet; however, it should be considered as an alternative treatment. Table 1 provides a brief summary of the papers reporting use of steroid-sparing therapies in AH, adding to the previous summary by Joshi et al. [3]. The case reports indicate good response to azathioprine and rituximab in patients with progression or recurrence as well as adverse effects to glucocorticoids.

The current case illustrates that, in treatment of AH where surgery and traditional immunosuppressive therapy is insufficient or intolerable, monoclonal antibody-directed therapy such as rituximab can be a preferable alternative.

**Abbreviations**

AH: Autoimmune hypophysitis; ACTH: Adrenocorticotropic hormone; TSH: Thyroid-stimulating hormone; MRI: Magnetic resonance imaging.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MK and TBO conceptualized and designed the work. MK analyzed and interpreted the patient data, drafted the manuscript and revised the manuscript critically for important intellectual content. TBO, DG, and MSA revised the manuscript critically for important intellectual content. All authors agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

**Funding**

No funding.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Internal Medicine, Hospital of Littlebelt, Kolding, Denmark.
2. Department of Radiology, Odense University Hospital, Odense, Denmark.
3. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.

**Received**: 24 May 2021 **Accepted**: 8 October 2021

**Published online**: 15 December 2021

**References**

1. Chiolo S, Capoluongo ED, Tartaglione T, Giampietro A, Bianchi A, Giustina A, et al. The changing clinical spectrum of hypophysitis. Trends Endocrinol Metab. 2019;30(9):590–602.
2. Brandes JC, Cerletty JM. Pregnancy in lymphocytic hypophysitis: case report and review. Wis Med J. 1989;88(1):29–32.
3. Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2019;179(3):R151–63.
4. Pietre A, Salvatori R. Hypophysitis: In: Endotext. South Dartmouth (MA); 2000. https://www.ncbi.nlm.nih.gov/pubmed/30160871.
5. Yuen KCJ, Popovic V, Trainer PJ. New causes of hypophysitis. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101276.
6. Albarel F, Castinetti F, Bruet T. Management of endocrine disease: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019;181(3):R107–18.
7. Bellastella G, Maieron Mi, Bizzarro A, Giugliano D, Esposito K, Bellastella A, et al. Revisitation of autoimmune hypophysitis: knowledge
and uncertainties on pathophysiological and clinical aspects. Pituitary. 2016;19(6):625–42.
8. Leung GK, Lopes MB, Thorner MD, Vance ML, Laws ER Jr. Primary hypophysitis: a single experience in 16 cases. J Neurosurg. 2004;101(2):262–71.
9. Kluczynski L, Gilis-Januszewska A, Rogozinski D, Pantofinski J, Hubalewska-Dydejczyk A. Hypophysitis—new insights into diagnosis and treatment. Endokrynol Pol. 2019;70(3):260–9.
10. Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014;13(4–5):412–6.
11. Caturegli P, Newschaffer C, Olivieri A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26(5):599–614.
12. Hana V, Salenave S, Chanson P. Pituitary stalk enlargement in adults. Neuroendocrinology. 2020;110:809.
13. Schreckinger M, Francis T, Rajah G, Jagannathan J, Guthikonda M, Mittal S. Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg. 2012;116(6):1318–23.
14. Xu C, Ricciuti A, Caturegli P, Keene CD, Kargi AY. Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab. Pituitary. 2013;18(4):441–7.
15. Honegger J, Buchfelder M, Schlaffer S, Droste M, Werner S, Strasburger C, et al. Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100(9):3460–9.
16. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. 2006;27(4):371–97.
17. Citterio G, Reni M, Gatta G, Ferretti AJM. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017;113:97–110.
18. Gutenberg A, Hans V, Puchner MJ, Kreutzer J, Bruck W, Caturegli P, et al. Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol. 2006;155(1):101–7.
19. Lecube A, Francisco G, Rodriguez D, Ortega A, Codina A, Hernandez C, et al. Lymphocytic hypophysitis successfully treated with azathioprine: first case report. J Neurol Neurosurg Psychiatry. 2003;74(11):1581–3.
20. De Bells C, Bellastella G, Saggio A, Guastaferrro S, Cazzolino D, et al. Rituximab-induced remission of autoimmune hypophysitis and primary immune thrombocytopenia in a patient with autoimmune polyendocrine syndrome type 4. Expert Rev Endocrinol Metab. 2014;9(4):313–7.
21. Byrne TN, Stone JH, Pillai SS, Rapalino O, Deshpande V. Case records of the Massachusetts General Hospital. Case 31–2016. A 53-year-old man with diplopia, polydipsia, and polyuria. N Engl J Med. 2016;375(15):1469–80.
22. Curto L, Granata F, Torre ML, Tramarchi F, Cannavo S. Unusual magnetic resonance imaging finding in a male with lymphocytic hypophysitis mimicking a pituitary tumor. J Endocrinol Invest. 2010;33(2):128–9.
23. Lu Z, Yang G, Ba J, Dou J, Mu Y, Lu J. Spontaneous pregnancy in a patient with a relapse of lymphocytic hypophysitis successfully treated with azathioprine and glucocorticoids. Endocrine. 2011;39(3):296–7.
24. Wang XL, Lu JM, Yang LJ, Lu ZH, Dou JT, Mu YM, et al. A case of relapsed autoimmune hypothalaminitis successfully treated with methylprednisolone and azathioprine. Neuro Endocrinol Lett. 2008;29(6):874–6.
25. Yang GQ, Lu ZH, Gu WJ, Du J, Guo QH, Wang XL, et al. Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases. Endocr J. 2011;58(8):675–83.
26. Katsiveli P, Fakiotaki M, Voulgaris N, Papastasiou L, Konidari T, Lymperopoulos K, et al. A complicated case of primary hypophysitis with bilateral intracavernous carotid artery occlusion. Hormones (Athens). 2016;15(2):291–6.
27. Curto L, Torre ML, Cotta OR, Losa M, Terenzi MR, Santarpia L, et al. Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities—report of a case and literature review. ScientificWorldJournal. 2010;10:126–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.